CAS 2382378-57-4
:Monomethyl auristatin E intermediate-17
Description:
Monomethyl auristatin E intermediate-17 is a synthetic compound primarily used in the field of medicinal chemistry, particularly in the development of antibody-drug conjugates (ADCs) for cancer therapy. This compound is characterized by its potent cytotoxic properties, which are attributed to its ability to inhibit microtubule polymerization, thereby disrupting cellular mitosis. It typically features a complex structure that includes a peptide component linked to a cytotoxic agent, allowing for targeted delivery to cancer cells while minimizing effects on healthy tissues. The compound is often evaluated for its stability, solubility, and efficacy in preclinical studies. Additionally, its safety profile is assessed to ensure that it can be used effectively in therapeutic applications. As with many synthetic intermediates, handling requires caution due to potential toxicity, and it is usually managed under controlled laboratory conditions. Overall, Monomethyl auristatin E intermediate-17 represents a significant advancement in the design of targeted cancer therapies.
Formula:C27H35NO7S
Synonyms:- Monomethyl auristatin E intermediate-17
Sort by
The purity filter is not visible because current products do not have associated purity data for filtering.
Found 1 products.
Monomethyl auristatin E intermediate-17
CAS:<p>MonomethylauristatinE intermediate-17 is an intermediate compound used in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) functions as a microtubule/tubulin inhibitor with anticancer properties. It is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs).</p>Formula:C27H35NO7SMolecular weight:517.63
